TP53 and neoplasm: MiR-29 inhibits tumor growth by increasing p53 expression, activates the p53-p21 and p16 PRB pathways via regulation of CNOT6, and impairs the proliferation of muscle progenitor cells in elderly mice by binding to the 3’-UTR of p85a, IGF-1, and B-Myb [61, 62].